CD274 and non-small cell lung carcinoma: Several clinical studies have shown that Pembrolizumab, a monoclonal antibody that prevents the PD-1/PD-L1 linking, is associated with better disease control and improved OS, with a reduced toxicity profile compared to chemotherapy in patients affected by advanced NSCLC [5–9].